FDG-PET/CT could improve treatment for NSCLC patients

Using FDG-PET/CT, researchers in Italy have found a correlation between cell-free...Read more on AuntMinnie.comRelated Reading: Study questions value of CT scans after NCSLC surgery PET identifies cell mutations in NSCLC patients ASTRO: Negative PET/CT doesn't always mean dormant NSCLC SNMMI: FDG-PET can monitor immunotherapy for NSCLC
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

Conclusion: In this retrospective study of patients with NSCLC treated with PD-1 antibodies, tumor response by standard PERCIST was significantly correlated with OS. Modifications of the PERCIST criteria to account for inflammatory lesions did not substantially improve the prognostic value of tumor response on FDG PET. While these results are promising for the use of FDG PET for monitoring immunotherapy, further studies are warranted to understand the impact of the type of immunotherapy and the timing of the FDG PET scans on response assessment. table 1PERCIST5 (modified)CMRPMRSMDPMDTotalPERCIST1 (modified)CMR70007PMR01020...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer II: PET-Derived Parameters as Predictors of Response to Therapy Source Type: research
AbstractPurpose of ReviewLung cancer is the major cause of cancer mortality in the USA. In this review, we aim to provide a general update on the current status of non-small cell lung cancer (NSCLC) management.Recent FindingsNovel approaches in the diagnosis and treatment of non-small cell lung cancer have been made recently and this was revolutionary in the way lung cancer management has changed even-though the improvement in overall survival remains modest. Furthermore, lung cancer screening using low-dose computed tomography scan has shown benefit in high-risk populations.SummaryThe diagnosis of lung cancer has evolved ...
Source: Current Respiratory Care Reports - Category: Respiratory Medicine Source Type: research
Authors: Nagasaka M, Gadgeel SM Abstract INTRODUCTION: Adjuvant platinum based chemotherapy is accepted as standard of care in stage II and III non-small cell lung cancer (NSCLC) patients and is often considered in patients with stage IB disease who have tumors ≥ 4 cm. The survival advantage is modest with approximately 5% at 5 years. Areas covered: This review article presents relevant data regarding chemotherapy use in the perioperative setting for early stage NSCLC. A literature search was performed utilizing PubMed as well as clinical trial.gov. Randomized phase III studies in this setting including adjuvant...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
We examined the association between the frequency of PD‐L1 protein expression and the maximum standardized uptake value (SUVmax) in preoperative 18F‐FDG PET/CT. The cut‐off values for SUVmax were determined by receiver operating characteristic curve analyses. The SUVmax was significantly higher in nonsmall cell lung cancer (NSCLC) patients with PD‐L1 protein expression compared with those without PD‐L1 protein expression (P 
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
We report a rare case of transformation of non-small cell lung cancer (NSCLC) to small cell lung cancer (SCLC), without epidermal growth factor receptor (EGFR) gene mutation, during immunotherapy treatment with nivolumab. A 75-year-old man was referred to our hospital following the observation of a 64 mm mass in a chest computed tomography (CT) scan. A transbronchial biopsy of the mass identified the pathological presence of poorly differentiated NSCLC, with no histological signs of SCLC. No mutations were identified in the EGFR gene. A clinical diagnosis of NSCLC (cT3N3M1a, stage IV) was made following a positron emission...
Source: Respiratory Medicine Case Reports - Category: Respiratory Medicine Source Type: research
ConclusionsImmune-related response evaluations using irRECIST1.1 in advanced NSCLC patients treated with nivolumab resulted in the identical response rate and longer TTP compared to RECIST1.1. No pseudoprogression cases were observed during the study. Adrenal lesions and lymph nodes were more responsive and liver lesions were less responsive to nivolumab.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Pseudo progression is only seen in a small part of patients treated with immunotherapy. With little tumor burden a treatment continuation can be feasible. Also patients who are not considered fit for second line chemotherapy may continue treatment. Aggressive tumor growth or high tumor load should stay a domain of conventional second line chemotherapy.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 11.1 Lung Cancer Source Type: research
Conclusions: This paper aims to alert for this rare and aggressive tumor, affecting mostly smoking male, which remains poorly explored. The better knowledge of PSC biology and molecular profile is critical for understanding the role of immunotherapy and targeted agents in this difficult to treat disease.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: 11.1 Lung Cancer Source Type: research
Conclusions The utility of FDG-PET in patients with NSCLC on immune blockade therapy appeared to be similar to what has been reported with conventional chemotherapeutic treatments, with early metabolic response predicting subsequent benefit. Baseline whole-body metabolic tumor volume was a strong negative prognostic factor for OS. Summary dual-time-point data did not provide incremental value.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer I Source Type: research
BACKGROUND: Metastatic non-small cell lung cancer (NSCLC) tumors have adopted methods to evade immune detection and/or clearance. This can occur via overexpression of programmed cell death ligand 1 (PD-L1). Response rate, progression free survival and overall survival with PD-1 inhibitors are greater in tumors with high tumor PD-L1 expression (Garon et al, NEJM 2015, Paz-Ares et al, ASCO 2015). There has been interest in using PD-L1 tumor expression as a treatment selection criterion. Currently available methods of screening involve invasive tumor biopsy followed by histological grading of PD-L1 levels. Biopsies allow samp...
Source: Molecular Cancer Therapeutics - Category: Cancer & Oncology Authors: Tags: Immune Monitoring/Clinical Correlates: Poster Presentations - Proffered Abstracts Source Type: research
More News: CT Scan | Immunotherapy | Italy Health | Non-Small Cell Lung Cancer | PET Scan | Study